Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | SCN4A | P35499 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.57 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31463178 | 1.00 | CYP2D6 (0.57) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL31544625 | 1.00 | CYP2D6 (0.57) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL3701926 | 0.86 | SCN10A (0.57) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL10987104 | 0.83 | CYP2D6 (0.50) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL3708084 | 0.83 | CYP2D6 (0.54) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL6373751 | 0.83 | MAPK1 (0.54) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL11067545 | 0.80 | CYP2D6 (0.50) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL30413401 | 0.79 | SCN9A (0.61) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL978226 | 0.79 | SCN9A (0.61) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL10811842 | 0.79 | SCN9A (0.75) | CYP2D6MAOAMAPK1ADRA1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0086502-B1 | SUBSTITUTED AROMATIC TRIAZINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-03-25 | — | — | EP | claimed |
| US-4563456-A | 1,2,4-Triazines for treating gastrointestinal motility dysfunction | WILLIAM H. RORER, INC. (US) | 1986-01-07 | — | — | US | claimed |
| EP-0024351-B1 | SOLID PHARMACEUTICAL FORMULATION CONTAINING SUBSTITUED PHENYL-TRIAZINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-10-31 | — | — | EP | claimed |
| EP-0086502-A2 | Substituted aromatic triazines | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-08-24 | — | — | EP | claimed |
| US-4311701-A | Treatment of convulsions with triazines | BURROUGHS WELLCOME CO, A CORP.OF N.C. | 1982-01-19 | — | — | US | claimed |
| EP-0024351-A1 | Solid pharmaceutical formulation containing substitued phenyl-triazines | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-04 | — | — | EP | claimed |
| EP-2043656-B1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIV GREENWICH (GB) | 2014-02-12 | — | — | EP | disclosed |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2013-01-03 | — | — | US | disclosed |
| US-8268823-B2 | Medical use of triazine derivatives | UNIVERSITY OF GREENWICH (GB) | 2012-09-18 | — | — | US | disclosed |
| US-20090291954-A1 | Medical Use of Triazine Derivatives | UNIVERSITY OF GREENWICH (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-2043656-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | University of Greenwich (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008007149-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2008-01-17 | — | — | WO | disclosed |
| US-6329521-B2 | Process for preparing substituted benzoyl cyanide amidinohydrazones | CHEMAGIS, LTD. (IL) | 2001-12-11 | — | — | US | disclosed |
| US-20010025118-A1 | Process for preparing substituted benzoyl cyanide amidinohydrazones | CHEMAGIS LTD. (IL) | 2001-09-27 | — | — | US | disclosed |
| EP-1127873-A2 | Process for preparing substituted Benzoyl Cyanide Amidinohydrazones | Chemagis Ltd. (IL) | 2001-08-29 | — | — | EP | disclosed |
| EP-0086502-B1 | SUBSTITUTED AROMATIC TRIAZINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-03-25 | — | — | EP | disclosed |
| EP-0024351-B1 | SOLID PHARMACEUTICAL FORMULATION CONTAINING SUBSTITUED PHENYL-TRIAZINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-10-31 | — | — | EP | disclosed |
| EP-0086502-A2 | Substituted aromatic triazines | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-08-24 | — | — | EP | disclosed |
| US-4311701-A | Treatment of convulsions with triazines | BURROUGHS WELLCOME CO, A CORP.OF N.C. | 1982-01-19 | — | — | US | disclosed |
| EP-0024351-A1 | Solid pharmaceutical formulation containing substitued phenyl-triazines | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025118-A1 | Process for preparing substituted benzoyl cyanide amidinohydrazones | SLC6A19, CPS1, SLC1A5 | CYP2D6 101/4885MAOA 1489/4885MAPK1 850/4885 |
| US-20090291954-A1 | Medical Use of Triazine Derivatives | KCNH1, KCNJ1, KCNN1 | CYP2D6 418/4885MAOA 803/4885MAPK1 2420/4885 |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | KCNJ1, KCNH1, KCNJ11 | CYP2D6 877/4885MAOA 1019/4885MAPK1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.